title: [Bone prevention in prostate cancer].
abstract: The bone loss and the fracture risk are enhanced in patients with hormonal deprivation for prostate cancer. The demineralisation can be quantified by BMD (Bone Mineral Density) and prevented by lifestyle and diet therapeutics or new therapeutic agents. These agents may have a preventive effect on metastasis occurrence, but it has to be confirmed. An intra-venous biphosphonate or a sub-cutaneous RANK-inhibitor administration prevent from bone metastasis-related events.
authors.affiliation: Service d'Urologie, Hôpital Bicêtre, 78, rue du Général Leclerc, 94275 Le Kremlin- Bicêtre Cedex, France. thomas.bessede@gmail.com
authors.forename: T
authors.initials: T
authors.lastname: Bessede
authors.forename: N
authors.initials: N
authors.lastname: Houede
authors.forename: T
authors.initials: T
authors.lastname: Lebret
mesh_terms: D001859:Bone Neoplasms / Q000517:prevention & control* / Q000556:secondary; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000209:etiology / Q000517:prevention & control*; D011471:Prostatic Neoplasms / Q000473:pathology / Q000628:therapy*